Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report)’s share price reached a new 52-week high during trading on Monday . The company traded as high as $28.00 and last traded at $27.9710, with a volume of 228286 shares traded. The stock had previously closed at $26.87.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on BCAX. Bank of America assumed coverage on shares of Bicara Therapeutics in a research report on Wednesday, March 25th. They set a “buy” rating and a $35.00 target price for the company. Guggenheim started coverage on shares of Bicara Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $42.00 price objective for the company. Wedbush reiterated an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Citizens Jmp reissued a “market outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Finally, Morgan Stanley lifted their target price on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Bicara Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $30.27.
Get Our Latest Stock Report on BCAX
Bicara Therapeutics Price Performance
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). As a group, sell-side analysts expect that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current year.
Insiders Place Their Bets
In other Bicara Therapeutics news, CEO Claire Mazumdar sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $23.61, for a total value of $354,150.00. Following the transaction, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at $8,550,408.72. This represents a 3.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Raben sold 5,500 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $22.88, for a total value of $125,840.00. Following the completion of the transaction, the insider directly owned 55,286 shares in the company, valued at approximately $1,264,943.68. The trade was a 9.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 63,900 shares of company stock worth $1,420,704. Company insiders own 13.80% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in BCAX. Legal & General Group Plc increased its position in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Bicara Therapeutics in the fourth quarter valued at about $45,000. Larson Financial Group LLC raised its stake in Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after buying an additional 3,595 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after buying an additional 4,585 shares in the last quarter.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Featured Stories
- Five stocks we like better than Bicara Therapeutics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
- onsemi: What the Market Gets Wrong, You Can Get Right
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
